Methadone Effects on Zidovudine (ZDV, AZT) Disposition

Inclusion Criteria

Patients must have:

• Documented HIV infection.
• CD4 count 100 - 500 cells/mm3.
• No active opportunistic infection or wasting syndrome.
• Opiate addiction or prior enrollment in a methadone treatment program (methadone recipients only).
• Admission to General Clinical Research Center at Yale-New Haven Hospital for clonidine detoxification (methadone recipients only).

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Inadequate IV access.
• Benzodiazepine abuse.

Concurrent Medication:

Excluded:

• Amiodarone.
• Anesthetics, general.
• Azithromycin.
• Barbiturates.
• Carbamazepine.
• Cimetidine.
• Ciprofloxacin.
• Clarithromycin.
• Dexamethasone.
• Disulfiram.
• Erythromycin.
• Fluoroquinolones.
• Fluoxetine.
• Gestodene.
• Hydrochlorothiazide.
• Hypoglycemics, oral.
• Isoniazid.
• Itraconazole.
• Ketoconazole.
• Levomepromazine.
• MAO inhibitors.
• Methoxsalen.
• Nafcillin.
• Narcotic analgesics.
• Naringenin.
• Norethindrone.
• Omeprazole.
• Pentazocine.
• Phenothiazines.
• Phenytoin.
• Quinidine.
• Ranitidine.
• Rifabutin.
• Rifampin.
• Sedative Hypnotics.
• Sulfaphenazole.
• Tranquilizers (except at discretion of investigator and protocol chair).
• Tricyclic antidepressants.
• Troleandomycin.
• Warfarin.

Prior Medication:

Excluded within 4 weeks prior to study entry:

• Rifampin or its derivatives.
• Phenytoin.
• Barbiturates.
• Cimetidine.
• Other drugs known to induce or inhibit hepatic microsomal enzymes.

Excluded within 14 days prior to study entry:

• Any other experimental drug.
• Drugs with known nephrotoxic potential.

Excluded within 72 hours prior to study entry:

• Amiodarone.
• Anesthetics, general.
• Azithromycin.
• Carbamazepine.
• Ciprofloxacin.
• Clarithromycin.
• Dexamethasone.
• Disulfiram.
• Erythromycin.
• Fluoroquinolones.
• Fluoxetine.
• Gestodene.
• Hydrochlorothiazide.
• Hypoglycemics, oral.
• Isoniazid.
• Itraconazole.
• Ketoconazole.
• Levomepromazine.
• MAO inhibitors.
• Methoxsalen.
• Nafcillin.
• Narcotic analgesics.
• Naringenin.
• Norethindrone.
• Omeprazole.
• Pentazocine.
• Phenothiazines.
• Quinidine.
• Ranitidine.
• Rifabutin.
• Sedative Hypnotics.
• Sulfaphenazole.
• Tranquilizers (except at discretion of investigator and protocol chair).
• Tricyclic antidepressants.
• Troleandomycin.
• Warfarin.

Continued active drug or alcohol abuse or dependence that would decrease the probability of study completion.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety